이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Beamion LUNG-2: Zongertinib(BI 1810631)가 표준 치료와 비교하여 HER2 돌연변이가 있는 진행성 비소세포폐암 환자에게 도움이 되는지 여부를 테스트하기 위한 연구

2026년 9월 30일 업데이트: Boehringer Ingelheim

Beamion LUNG-2: 절제 불가능, 국소 진행성 또는 전이성 비편평 비편평증 환자의 1차 치료로서 표준 치료와 비교하여 경구 투여된 BI 1810631을 평가하는 제3상, 공개, 무작위 배정, 활성 대조, 다기관 시험 HER2 티로신 키나제 도메인 돌연변이가 있는 소세포 폐암

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy.

Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein.

Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. Some visits may be conducted remotely later in the study if approved by the study doctor. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.

연구 개요

연구 유형

중재적

등록 (실제)

428

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Amsterdam, 네덜란드, 1066 CX
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek Amsterdam (METC AVL)
      • Maastricht, 네덜란드, 6229 HX
        • Maastricht University Medisch Centrum
      • Drammen, 노르웨이, N-3004
        • Vestre Viken HF, Drammen Sykehus
      • Oslo, 노르웨이, 0379
        • Oslo Universitetssykehus HF, Radiumhospitalet
      • Kaohsiung City, 대만, 83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Taichung, 대만, 404
        • Chung Shan Medical University Hospital
      • Taipei, 대만, 100
        • National Taiwan University Hospital
      • Taipei, 대만, 106
        • National Taiwan University Cancer Center
      • Taoyuan, 대만, 330
        • Chang Gung Memorial Hospital, Linkou
      • Cheongiu, 대한민국, 28644
        • Chungbuk National University Hospital
      • Goyang, 대한민국, 10408
        • National Cancer Center
      • Incheon, 대한민국, 21565
        • Gachon University Gil Medical Center
      • Seoul, 대한민국, 05505
        • Asan Medical Center
      • Seoul, 대한민국, 06351
        • Samsung Medical Center
      • Seoul, 대한민국, 03181
        • Kangbuk Samsung Hospital
      • Seoul, 대한민국, 03722
        • Severance Hospital
      • Suwon, 대한민국, 16247
        • The Catholic University of Korea, St.Vincent's Hospital
      • Augsburg, 독일, 86156
        • Universitätsklinikum Augsburg
      • Berlin, 독일, 14089
        • Gemeinschaftskrankenhaus Havelhöhe gGmbH
      • Cologne, 독일, 50937
        • Universitätsklinikum Köln (AöR)
      • Dresden, 독일, 01307
        • Universitätsklinikum Carl Gustav Carus Dresden
      • Giessen, 독일, 35392
        • Justus-Liebig Universität Gießen
      • Heidelberg, 독일, 69126
        • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
      • Oldenburg, 독일, 26121
        • Pius-Hospital, Oldenburg
      • Tübingen, 독일, 72076
        • Universitätsklinikum Tübingen
      • Mexico City, 멕시코, 03100
        • Health Pharma Professional Research S.A. de C.V.
      • México, 멕시코, 14080
        • Instituto Nacional de Cancerologia
      • México, 멕시코, 06760
        • Centro Oncologico Personalizado
      • Veracruz, 멕시코, 91900
        • FAICIC S de RL de C.V.
    • Alabama
      • Huntsville, Alabama, 미국, 35805
        • Clearview Cancer Institute
    • Arizona
      • Bullhead City, Arizona, 미국, 86442
        • Pioneer Research Center - Bullhead City
    • California
      • Beverly Hills, California, 미국, 90212
        • Precision NextGen Oncology
      • Fresno, California, 미국, 93710
        • ClinRé 001-022 (Premier Cancer Care and Infusion Center)
      • Glendale, California, 미국, 91203
        • OPN Healthcare, Inc.
      • La Jolla, California, 미국, 92037
        • Scripps Green Hospital
      • Los Angeles, California, 미국, 90067
        • Valkyrie Clinical Trials
      • San Diego, California, 미국, 92123
        • Sharp Memorial Hospital
    • Missouri
      • Bridgeton, Missouri, 미국, 63044
        • St. Louis Cancer Care, LLP
      • Springfield, Missouri, 미국, 65807
        • Oncology Hematology Associates
    • Nevada
      • Reno, Nevada, 미국, 89511
        • Cancer Care Specialists
    • New York
      • Lake Success, New York, 미국, 11042
        • Northwell Health
      • The Bronx, New York, 미국, 10461
        • Montefiore Medical Center
    • North Carolina
      • Wilson, North Carolina, 미국, 27893
        • Regional Medical Oncology Center
    • Ohio
      • Canton, Ohio, 미국, 44718
        • Gabrail Cancer Center
    • South Carolina
      • Rock Hill, South Carolina, 미국, 29732
        • Carolina Blood and Cancer Care Associates, PA
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • SCRI Oncology Partners
    • Utah
      • Salt Lake City, Utah, 미국, 84112
        • Huntsman Cancer Institute
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists, PC
    • Washington
      • Edmonds, Washington, 미국, 98026
        • Swedish Cancer Institute
      • Issaquah, Washington, 미국, 98029
        • Swedish Cancer Institute
      • Seattle, Washington, 미국, 98104
        • Swedish Cancer Institute
      • Anderlecht, 벨기에, 1070
        • Brussels - HOSP Jules Bordet
      • Ghent, 벨기에, 9000
        • Universitair Ziekenhuis Gent
      • Leuven, 벨기에, 3000
        • UZ Leuven
      • Bento Gonçalves, 브라질, 95700-084
        • Associacao Dr. Bartholomeu Tacchini
      • Londrina, 브라질, 86015-520
        • Hospital do Câncer de Londrina
      • Porto Alegre, 브라질, 90610-000
        • Hospital Sao Lucas da PUCRS
      • Rio de Janeiro, 브라질, 22250-905
        • OncoClinicas Rio de Janeiro
      • Santo André, 브라질, 09060-650
        • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
      • São José do Rio Preto, 브라질, 15090-000
        • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto
      • São Paulo, 브라질, 01246-000
        • ICESP - Instituto do Cancer do Estado de Sao Paulo
      • Gothenburg, 스웨덴, 413 45
        • Sahlgrenska Universitetsjukhuset
      • Stockholm, 스웨덴, 171 76
        • Karolinska Universitetssjukhuset Solna
      • A Coruña, 스페인, 15006
        • Complejo Hospitalario Universitario A Coruña
      • Alicante, 스페인, 03010
        • Hospital General Universitario de Alicante
      • Barcelona, 스페인, 08035
        • Hospital Universitari Vall d'Hebron
      • Barcelona, 스페인, 08026
        • Hospital Santa Creu i Sant Pau
      • Barcelona, 스페인, 08908
        • Hospital Duran i Reynals
      • Bilbao, 스페인, 48013
        • Hospital de Basurto
      • Madrid, 스페인, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, 스페인, 28046
        • Hospital Universitario La Paz
      • Madrid, 스페인, 28009
        • Hospital General Universitario Gregorio Marañón
      • Madrid, 스페인, 28034
        • Hospital Universitario Ramon Y Cajal
      • Málaga, 스페인, 29010
        • Hospital Regional Universitario de Malaga
      • Seville, 스페인, 41013
        • Hospital Virgen del Rocio
      • Valencia, 스페인, 46010
        • Hospital Clinico Universitario de Valencia
      • Singapore, 싱가포르, 168583
        • National Cancer Centre Singapore
      • Singapore, 싱가포르, 119228
        • National University Hospital-Singapore-22806
      • CABA, 아르헨티나, 1430
        • Clinica Adventista Belgrano
      • Ciudad Autónoma de Bs As, 아르헨티나, C1426ANZ
        • Instituto Medico Especializado Alexander Fleming
      • Córdoba, 아르헨티나, X5000
        • Instituto Oncologico de Cordoba
      • La Rioja, 아르헨티나, F5300COE
        • Centro Oncologico Riojano Integral (CORI)
      • Rosario, 아르헨티나, S2000DEJ
        • Instituto Medico de la Fundacion Estudios Clinicos
      • Edinburgh, 영국, EH4 2XU
        • Western General Hospital
      • Leicester, 영국, LE1 5WW
        • Leicester Royal Infirmary
      • London, 영국, SE1 9RT
        • Guy's Hospital
      • London, 영국, SW3 6JJ
        • The Royal Marsden Hospital, Chelsea
      • Sutton, 영국, SM2 5PT
        • The Royal Marsden Hospital, Sutton
      • Krems, 오스트리아, 3500
        • Krems University Hospital
      • Vienna, 오스트리아, 1210
        • Clinic Floridsdorf
      • Haifa, 이스라엘, 3109601
        • Rambam Medical Center
      • Kfar Saba, 이스라엘, 4428164
        • Meir Medical Center
      • Petah Tikva, 이스라엘, 49100
        • Rabin Medical Center Beilinson
      • Tel Aviv, 이스라엘, 6423906
        • Sourasky Medical Center
      • Bari, 이탈리아, 70124
        • Istituto Tumori Giovanni Paolo II
      • Candiolo (TO), 이탈리아, 10060
        • Istituto Di Candiolo
      • Catania, 이탈리아, 95123
        • Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
      • Naples, 이탈리아, 80131
        • Istituto Nazionale IRCCS Tumori Fondazione Pascale
      • Parma, 이탈리아, 43100
        • Azienda Ospedaliera Unversitaria di Parma
      • Roma, 이탈리아, 00161
        • AOU Policlinico Umberto I
      • Varese, 이탈리아, 21100
        • A. O. Ospedale Circolo Fond. Macchi
      • Aichi, Nagoya, 일본, 464-8681
        • Aichi Cancer Center Hospital
      • Aomori, Hirosaki, 일본, 036-8563
        • Hirosaki University Hospital
      • Chiba, Kashiwa, 일본, 277-8577
        • National Cancer Center Hospital East
      • Ehime, Matsuyama, 일본, 791-0280
        • Shikoku Cancer Center
      • Fukuoka, Fukuoka, 일본, 812-8582
        • Kyushu University Hospital
      • Hokkaido, Hakodate, 일본, 040-8611
        • Hakodate Goryoukaku Hospital
      • Hokkaido, Sapporo, 일본, 003-0804
        • Hokkaido Cancer Center
      • Ishikawa, Kanazawa, 일본, 920-8641
        • Kanazawa University Hospital
      • Kanagawa, Kawasaki, 일본, 216-8511
        • St. Marianna University Hospital
      • Kanagawa, Yokohama, 일본, 241-8515
        • Kanagawa Cancer Center
      • Kyoto, Kyoto, 일본, 602-8566
        • University Hospital Kyoto Prefectural University of Medicine
      • Miyagi, Sendai, 일본, 980-8574
        • Tohoku University Hospital
      • Okayama, Okayama, 일본, 700-8558
        • Okayama University Hospital
      • Osaka, Osaka, 일본, 541-8567
        • Osaka International Cancer Institute
      • Shizuoka, Sunto-gun, 일본, 411-8777
        • Shizuoka Cancer Center
      • Tokyo, Bunkyo-ku, 일본, 113-8431
        • Juntendo University Hospital
      • Tokyo, Bunkyo-ku, 일본, 113-8677
        • Komagome Hospital
      • Tokyo, Chuo-ku, 일본, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Koto-ku, 일본, 135-8550
        • Japanese Foundation for Cancer Research
      • Wakayama, Wakayama, 일본, 641-8510
        • Wakayama Medical University Hospital
      • Beijing, 중국, 100142
        • Beijing Cancer Hospital
      • Beijing, 중국, 1000021
        • Cancer Hospital of Chinese Academy of Medical Science
      • Chengdu, 중국, 610042
        • West China Hospital, Sichuan University
      • Fuzhou, 중국, 350014
        • Fujian Cancer Hospital
      • Guangzhou, 중국, 510080
        • Guangdong Provincial People's Hospital
      • Hangzhou, 중국, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, 중국, 310003
        • The First Affiliated Hospital, Zhejiang University
      • Hangzhou, 중국, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
      • Harbin, 중국, 150081
        • Harbin Medical University Cancer Hospital
      • Shanghai, 중국, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, 중국, 200032
        • Zhongshan Hospital Affiliated to Fudan University
      • Taizhou, 중국, 317099
        • Taizhou Hospital of Zhejiang Province
      • Wenzhou, 중국, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, 중국, 430022
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
      • Xiamen, 중국, 361003
        • First Affiliated Hospital of Xiamen University
      • Zhengzhou, 중국, 450008
        • Henan Cancer Hospital
      • Recoleta, 칠레, 8420383
        • Bradford Hill- Centro de Investigacion Clinica
      • Lisbon, 포르투갈, 1350-352
        • Hospital CUF Tejo
      • Lisbon, 포르투갈, 1769-001
        • Centro Hospitalar Lisboa Norte Hospital Pulido Valente
      • Porto, 포르투갈, 4100-180
        • Hospital CUF Porto
      • Lodz, 폴란드, 93-338
        • Polish Mother's Memorial Hospital - Research Institute
      • Poznan, 폴란드, 60-569
        • Greater Poland Center of Pulmonology and Thoracic Surgery
      • Poznan, 폴란드, 60693
        • Med Polonia Sp. z o.o
      • Warsaw, 폴란드, 02-781
        • Oncology Center-Maria Sklodowska-Curie Institute
      • Rio Piedras, 푸에르토 리코, 00935
        • Pan American Center for Oncology Trials, LLC
      • Bron, 프랑스, 69677
        • Hopital Louis Pradel
      • Lyon, 프랑스, 69373
        • CTR Leon Berard
      • Marseille, 프랑스, 13015
        • HOP Nord
      • Paris, 프랑스, 75248
        • INS Curie
      • Paris, 프랑스, 75020
        • HOP Tenon
      • Rennes, 프랑스, 35000
        • HOP Pontchaillou
      • Strasbourg, 프랑스, 67091
        • HOP Civil
      • Toulouse, 프랑스, 31059
        • Hôpital Larrey - CHU de Toulouse
      • Villejuif, 프랑스, 94805
        • Institut Gustave Roussy
    • New South Wales
      • Randwick, New South Wales, 호주, 2031
        • Prince of Wales Hospital-Randwick-66496
      • St Leonards, New South Wales, 호주, 2065
        • Royal North Shore Hospital-St Leonards-20807
    • Queensland
      • Woolloongabba, Queensland, 호주, 4102
        • Princess Alexandra Hospital
    • Victoria
      • Heidelberg, Victoria, 호주, 3084
        • Austin Health
    • Western Australia
      • Subiaco, Western Australia, 호주, 6008
        • St John of God Subiaco Hospital
      • Hong Kong, 홍콩, 999077
        • Queen Mary Hospital
      • Hong Kong, 홍콩, 999077
        • Princess Margaret Hospital
      • Hong Kong, 홍콩, 51727
        • Queen Elizabeth Hospital-Hong Kong-51727

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion criteria:

  1. Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
  2. Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.
  3. Histologically or cytologically confirmed diagnosis of an advanced and/or metastatic non-squamous Non-small cell lung cancer (NSCLC).
  4. Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.
  5. An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor.
  6. Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy.
  7. Presence of at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST) 1.1, as determined by the local site investigator/radiology assessment.
  8. Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the Summaries of Product Characteristics (SmPC)/Product Information.

Further inclusion criteria apply.

Exclusion criteria:

  1. Previous or concomitant malignancies other than the one treated in this trial within the last 5 years, except;

    • effectively treated non-melanoma skin cancers
    • effectively treated carcinoma in situ of the cervix
    • effectively treated ductal carcinoma in situ
    • other effectively treated malignancy that is considered cured by local treatment
  2. Tumors with targetable alterations with approved available therapy.

  3. Lung-specific intercurrent clinically significant severe illness based on investigators assessment.

  4. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.

  5. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening, e.g. hip replacement.

  6. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug.

  7. History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥ III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization.

  8. Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block.

Further exclusion criteria apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Experimental treatment arm

zongertinib only

zongertinib

다른 이름들:
  • BI 1810631, Hernexeos®
활성 비교기: Comparator arm

pembrolizumab plus platinum-pemetrexed chemotherapy

pembrolizumab

다른 이름들:
  • 키트루다®

platinum-pemetrexed chemotherapy

platinum-pemetrexed chemotherapy

platinum-pemetrexed chemotherapy

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent review
기간: up to 4 years and 5 months

PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.

up to 4 years and 5 months

2차 결과 측정

결과 측정
측정값 설명
기간
NSCLC-SAQ 호흡곤란 영역 점수의 기준선에서 25주차까지의 변화
기간: 기준시점, 25주차
기준시점, 25주차
NSCLC-SAQ 기침 영역 점수의 기준선에서 25주차까지의 변화
기간: 기준시점, 25주차
기준시점, 25주차
NSCLC-SAQ 식욕 영역 점수의 기준선에서 25주차까지의 변화
기간: 기준시점, 25주차
기준시점, 25주차
NSCLC-SAQ 피로 영역 점수의 기준선에서 25주차까지의 변화
기간: 기준시점, 25주차
기준시점, 25주차
CTCAE(Common Terminology Criteria for Adverse Events) 버전 5.0에 따라 등급이 지정된 치료 기간 중 부작용(AE)의 발생
기간: 최대 53개월
최대 53개월
CTCAE 버전 5.0에 따라 등급이 지정된 치료 기간 중 심각한 AE(SAE) 발생
기간: 최대 53개월
최대 53개월
Key secondary endpoint: Overall Response (OR) according to RECIST 1.1 determined by blinded central independent review
기간: up to 53 months

OR is defined as confirmed best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to RECIST 1.1 from date of randomization until the earliest of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent.

up to 53 months
Key secondary endpoint: Change from baseline to Week 25 of Non-small cell lung cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score
기간: at baseline, at week 25

The NSCLC-SAQ is a 7-item patient-reported outcome measure for use in adults to assess symptoms of advanced NSCLC.

It contains five domains and accompanying items that were identified as symptoms of NSCLC: cough (1 item), pain (2), dyspnea (1), fatigue (2), and appetite (1).

The (total) lowest score possible is 0, and the highest (total) score possible is 20. Higher scores indicate more severe symptoms.

at baseline, at week 25
Key secondary endpoint: Overall Survival (OS)
기간: up to 53 months

OS is defined as the time from randomization until death from any cause.

up to 53 months
Duration of response (DoR), determined by blinded central independent review
기간: up to 53 months

DoR is defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response.

up to 53 months
PFS determined by blinded central independent review
기간: up to 53 months

PFS is defined as the time from randomization until tumor progression or death from any cause, whichever occurs earlier.

up to 53 months
Bi-compartmental PFS, determined by blinded central independent review
기간: up to 53 months

Bi-compartmental PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.

up to 53 months
OR determined by blinded central independent review
기간: up to 53 months

OR is defined as confirmed best overall response of CR or PR, from date of randomization until the earliest progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent.

up to 53 months
Change from baseline to Week 25 in the NSCLC-SAQ pain domain score
기간: at baseline, at week 25

The individual NSCLC-SAQ items use a five-point verbal rating scale from "No <symptom> At All" to "Very severe <symptom>" or from "Never to Always," corresponding to an (item) score of 0 to 4. A higher score indicates more severe symptoms.

at baseline, at week 25
Change from baseline to Week 25 in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) physical functioning domain score
기간: at baseline, at week 25

The EORTC QLQ-C30 is a quality of life questionnaire. It ranges from 0 to 100, higher scores equal worse outcome.

at baseline, at week 25

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 2월 9일

기본 완료 (추정된)

2026년 12월 10일

연구 완료 (추정된)

2028년 1월 28일

연구 등록 날짜

최초 제출

2023년 11월 22일

QC 기준을 충족하는 최초 제출

2023년 11월 22일

처음 게시됨 (실제)

2023년 11월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

IPD 공유 기간

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

IPD 공유 액세스 기준

For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다